Camlin Fine Sciences · NSE: CAMLINFINE · BSE: 532834

Q3 FY26 results · Oct–Dec 2025

Camlin Fine Sciences reported revenue from operations of ₹457.20 crore (up 5.5% from Q3 FY25) and net loss of ₹37.10 crore for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY26	Q3 FY25	YoY	Q2 FY26	QoQ
Revenue from operations	457.20	433.49	+5.5%	459.83	−0.6%
Other income	2.94	1.34	+119.7%	4.59	−36.0%
Total income	460.13	434.83	+5.8%	464.42	−0.9%
Profit before share of associates & JVs and tax	(27.60)	1.52	Turned loss	0.27	Turned loss
Share of profit/(loss) of associates & JVs	(0.25)	(1.85)		(0.36)
Net profit for the period	(37.10)	(7.47)	Loss widened	(14.95)	Loss widened
Attributable to shareholders of the company	(36.23)	(4.14)	Loss widened	(14.38)	Loss widened
EPS, basic (₹)	(1.91)	(0.24)	not comparable	(0.76)	Loss widened
Net margin (%)	-8.1	-1.7		-3.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY26	Q3 FY25	YoY	Q2 FY26	QoQ
Revenue from operations	218.92	205.07	+6.8%	244.04	−10.3%
Other income	5.77	6.82	−15.4%	10.19	−43.4%
Total income	224.69	211.89	+6.0%	254.24	−11.6%
Profit before tax	(17.27)	(7.19)	Loss widened	(3.81)	Loss widened
Net profit for the period	(13.00)	(5.63)	Loss widened	(3.64)	Loss widened
EPS, basic (₹)	(0.69)	(0.33)	not comparable	(0.19)	Loss widened
Net margin (%)	-5.9	-2.7		-1.5

Consolidated

Filed with BSE: 13 Feb 2026, 18:14 IST
Board meeting: 13 Feb 2026
Period: 01 Oct 2025 to 31 Dec 2025
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 13 Feb 2026, 18:14 IST
Board meeting: 13 Feb 2026
Period: 01 Oct 2025 to 31 Dec 2025
Review status: Unaudited
Source: XBRL filing on BSE